palonesetron
Phase 2CompletedDevelopment Stage
Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
Oct 27, 2009 → Dec 8, 2010
About palonesetron
palonesetron is a phase 2 stage product being developed by Eisai for Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC. The current trial status is completed. This product is registered under clinical trial identifier NCT01054456. Target conditions include Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01054456 | Phase 2 | Completed |
Competing Products
20 competing products in Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + Epoetin beta | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| PLX3397 + Temozolomide | Daiichi Sankyo | Phase 1/2 | 41 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| Roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 77 |
| ASP8825 | Astellas Pharma | Phase 1 | 33 |
| ASP015K | Astellas Pharma | Phase 1 | 33 |
| ASP7991 | Astellas Pharma | Phase 1 | 33 |
| Roxadustat + Epoetin Alfa | Astellas Pharma | Phase 3 | 77 |
| ATG-F | Astellas Pharma | Approved | 85 |
| Celecoxib | Astellas Pharma | Pre-clinical | 23 |
| roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| FK949E | Astellas Pharma | Phase 1 | 33 |